Portfolio Companies News
October 18, 2018GenSight Biologics reports positive...
• Clinically meaningful improvement of +15 ETDRS letters in visual acuity of treated eyes at Week 72 • Continuous bilateral improvement of both visual acuity and contrast sensitivity • Significantly higher proportion of drug-treated eyes achieved clinically meaningful improvement in contrast... read more
October 17, 2018Nordic Nanovector ASA: Change of Da...
Oslo, Norway, 17 October 2018 Nordic Nanovector ASA (OSE: NANO) announces it will present its results for the third quarter 2018 on Tuesday, 6 November 2018 (previously scheduled for Tuesday, 21 November), and will host a results presentation and webcast on the same day (details will be... read more
October 15, 2018Nomination Committee appointed in r...
Stockholm – October 15, 2018 – According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 17 May 2018, the Nomination Committee for the annual general meeting 2019 shall be composed of members appointed by t... read more
October 15, 2018Targovax Reports Encouraging Diseas...
15 October 2018 at 07:16:00 CET 16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients in the trial 19.5 months DFS in 2nd cohort who received an optimized dosing regimen 94% of patients had mutant RAS specific adaptive immune activation OSLO, Norway, Oct. 15... read more
October 12, 2018GenSight Biologics to present REVER...
Paris, France, October 12, 2018, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced to... read more
July 24, 2018Q2 2018 General Market Overview
Since the start in 1996, HealthCap funds have invested in 112 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.